Topical Drug Delivery Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Topical Drug Delivery Market is Segmented by Route of Administration (Dermal, Ophthalmic, Nasal, Oral, and Others), Product (Formulation (Solid, Semi-Solid (Cream, Ointment, and Others), Liquid) and Device (Inhaler, and Patch)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.

Market Snapshot

Topical Drug Delivery Market - 4
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The topical drug delivery market is expected to witness a CAGR of 8.5%, during the forecast period. With the delay in diagnosis and treatment, a significant impact on the topical drug demand was also observed. However, several clinical studies for topical treatments in COVID-19 are being carried out, which is expected to aid the market studied. For instance, in June 2020, researchers from Mansoura University initiated a clinical study with respect to a topical steroid and cyclosporin-A for the treatment of COVID-19 keratoconjunctivitis.

The prevalence of skin infections, like eczema, psoriasis, etc., and minor ailments, like acne, are increasing and having a big impact on the market, globally. Psoriasis effect is observed in people of all ages and in all countries. According to the study titled, 'National, regional, and worldwide epidemiology of psoriasis: a systematic analysis and modeling study', in May 2020, the incidence of psoriasis in adults was estimated to be around 30.3 per 100,000 person-years in Taiwan and about 321.0 per 100 000 person-years in Italy. Thus, in different geographic regions, with increased population sizes, there is a significant burden related to the skin, which is diagnosed at a prominent stage, and in such cases, the topic of drug delivery becomes more important. Hence, these statistics show that skin disease prevalence is increasing at a faster pace and is becoming a global burden, which is likely to positively impact the growth of the topical drug delivery market.

Some of the other factors that drive the market include the ease of drug delivery and technological advancements and innovations. In March 2019, Amneal Pharmaceuticals introduced the generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. It is used for the treatment of dementia caused due to Alzheimer's and Parkinson's disease. Such innovations are expected to flourish the market growth over the forecast period.

However, factors, such as regulatory scenario and pricing pressure, along with the high frequency of product recalls, are expected to obstruct the market studied. In November 2020, Health Canada recalled Picato, developed by Leo Pharma Inc., a topical drug used to treat skin lesions as this drug may have the potential to increase the risk of non-melanoma skin cancer. Thus, it can restrict market growth.

Scope of the Report

As per the scope of the report, topical drug delivery is a medication that is applied to a particular place on, or in the body, topically. Common skin diseases treated preferably by topical drug delivery systems include bacterial and fungal infections, inflammations, acne, psoriasis, hair, and skin problems. The topical drug delivery market is segmented by route of administration (dermal, ophthalmic, nasal, oral, and others), product (formulation (solid, semi-solid (cream, ointment, and others), liquid), and device (inhaler and patch)), and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America. The report offers the value (in USD million) for the above segments.

By Route of Administration
Dermal
Ophthalmic
Nasal
Oral
Others
By Product
Formulation
Solid
Semi-Solid
Creams
Ointment
Others
Liquid
Device
Inhaler
Patch
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Patch Segment is Expected to Hold Major Share in the Topical Drug Delivery Market

Patches in the devices segment are expected to hold a major share in the topical drug delivery market. Due to the emergence of COVID-19, a profound impact on the patch was also observed. In July 2020, Innoture received funding from the Welsh Government of about GBP 200,000 for its project: 'Self-Administration of SARS-CoV-2 Vaccine via Microlithographic 3D printed Microstructure Patches'. Such developments are expected to accelerate market growth in this segment.

There have been significant advantages associated with the skin patches that target a particular site in the body. The administration of drugs through the skin is also performed to achieve controlled, or prolonged drug delivery, and this route can be explored as an alternative to the oral route.

With the increasing product launches, the market studied is expected to flourish in this segment. For instance, in June 2020, Vektor Pharma introduced a generic version of Neupro patch (rotigotine), a transdermal patch that indicated against the symptoms of Parkinson's disease.

Furthermore, in December 2020, Agile Therapeutics Inc. introduced Twirla (levonorgestrel and ethinyl estradiol) transdermal system, which is a contraceptive patch. In October 2019, the United States Food & Drug Administration approved the 'SECUADO (asenapine) transdermal system' developed by Noven Pharmaceutical Inc. (Hisamitsu Pharmaceutical Co. Inc.). It is the only transdermal patch formulation that has been approved for the treatment of adults with schizophrenia. Thus, with the rising number of product launches and the advantages associated with skin patches, the market studied is expected to boost this segment.

Estimated New Cases of Melanoma of Skin, Globally, 2020 and 2040

North America is Expected to Dominate the Market Over the Forecast Period

North America has been accounted for the highest share in the topical drug delivery market. Due to the COVID-19 outbreak, the market is expecting to observe positive growth. This is mainly due to the novel treatment being developed. For instance, in August 2020, the United States Food and Drug Administration approved an over-the-counter ointment, 'T3X' developed by Advanced Penetration Technology. It has been approved against the SARS-CoV-2 virus. The studies have shown that T3X was successfully able to kill the virus within 30 seconds, due to the factors, such as the presence of a large number of pharmaceutical companies and drug delivery technology providers. As per the data provided by GLOBOCAN, 2020, about 105,000 new cases of melanoma skin cancer were reported in the North American region, which is expected to reach 142,000 by the year 2040. This growing burden of skin-related conditions is expected to accelerate the market growth.

Furthermore, growing product launches are also expected to boost the market growth in this region. For instance, in August 2020, the United States Food and Drug Administration (US FDA) approved Winlevi (clascoterone cream 1%) developed by Cassiopea SpA’s for the treatment of acne. Thus, the factors mentioned above are expected to thrive the market growth in this region during the forecast period.

Topical Drug Delivery Market 2

Competitive Landscape

The topical drug delivery market is moderately fragmented. The major players in the topical drug delivery market include Bayer AG, Cipla, Mylan NV, GlaxoSmithKline PLC, Galderma Holding SA, Novartis, Med Pharm, Johnson & Johnson (Janssen Pharmaceutical), Hisamitsu Pharmaceuticals, etc., provides these products across the world.

Recent Developments

  • In February 2021, Almirall and MC2 Therapeutics went under an exclusive agreement for the commercialization of its product 'Wynzora', a topical drug indicated against the treatment of plaque psoriasis.
  • In August 2020, LEO Pharma received United States Food and Drug Administration approval for its delgocitinib cream for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Prevalence of Skin Diseases

      2. 4.2.2 Technological Advancements and Innovations

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory Scenario and Pricing Pressure

      2. 4.3.2 High Frequency of Product Recalls

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Dermal

      2. 5.1.2 Ophthalmic

      3. 5.1.3 Nasal

      4. 5.1.4 Oral

      5. 5.1.5 Others

    2. 5.2 By Product

      1. 5.2.1 Formulation

        1. 5.2.1.1 Solid

        2. 5.2.1.2 Semi-Solid

          1. 5.2.1.2.1 Creams

          2. 5.2.1.2.2 Ointment

          3. 5.2.1.2.3 Others

        3. 5.2.1.3 Liquid

      2. 5.2.2 Device

        1. 5.2.2.1 Inhaler

        2. 5.2.2.2 Patch

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Cipla Limited

      3. 6.1.3 Mylan NV

      4. 6.1.4 Glaxosmithkline PLC

      5. 6.1.5 Hisamitsu Pharmaceuticals

      6. 6.1.6 Johnson & Johnson (Janssen Pharmaceutical)

      7. 6.1.7 Medpharm

      8. 6.1.8 Galderma Holding SA

      9. 6.1.9 Novartis International AG

      10. 6.1.10 Bausch Health Companies Inc.

      11. 6.1.11 3M

      12. 6.1.12 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Topical Drug Delivery Market market is studied from 2018 - 2026.

The Global Topical Drug Delivery Market is growing at a CAGR of 8.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bayer AG, Hisamitsu Pharmaceuticals, Novartis International AG, Galderma Holding SA, GlaxoSmithKline PLC are the major companies operating in Global Topical Drug Delivery Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!